Save up -80% on Rivaroxaban
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Xarelto
|$430.92||30 tablets/20 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Xarelto coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Rivaroxaban every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Rivaroxaban volume of distribution
Owing to its high plasma protein binding, rivaroxaban is not expected to be dialyzable. Volume of distribution at steady state is approximately 50 L (0.62 L/kg), indicating its low-to-moderate affinity to peripheral tissues.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Rivaroxaban
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Rivaroxaban mechanism of action
Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.
Dosage forms of Rivaroxaban
|Film-coated tablet||Oral use||10 mg|
|Film-coated tablet||Oral use||15 mg|
|Film-coated tablet||Oral use||2.5 mg|
BAY 59-7939 BAY59-7939
Humans and other mammals
Indication of Rivaroxaban
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (30mL/min).
Toxicity of Rivaroxaban
Excessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Rivaroxaban on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Rivaroxaban now!
What is a Xarelto?
Xarelto is a direct acting anticoagulant. Available in the form of film-coated tablets with an active substance content of 10, 15, and 20 milligrams. The active substance is micronized rivaroxaban.
Activation of factor X to form factor Xa through the internal and external coagulation paths plays a central role in the coagulation cascade. Factor Xa is a component of the emerging prothrombinase complex, whose action leads to the conversion of prothrombin to thrombin. As a result, these reactions lead to the formation of a fibrin thrombus and platelet activation by thrombin. One molecule of factor Xa catalyzes the formation of more than 1000 molecules of thrombin, which is called the “thrombin explosion.” The reaction rate of the factor Xa bound in prothrombinase increases by 300,000 times compared with that of the free factor Xa, which ensures a sharp jump in the level of thrombin. Selective inhibitors of factor Xa can stop the “thrombin explosion”. Thus, rivaroxaban influences the results of some specific or general laboratory tests used to assess coagulation systems. In humans, there is a dose-dependent inhibition of the activity of factor Xa.
Xarelto is rapidly absorbed – the maximum concentration in the blood is reached within two to four hours after consuming the pill. After ingestion, the majority of rivaroxaban (from 92 to 95 percent) binds to plasma proteins, the main binding component is serum albumin. When ingested, about two-thirds of the dose of rivaroxaban is metabolized and subsequently excreted in equal parts with feces and urine. The remaining third is excreted unchanged by direct renal excretion, primarily due to the active secretion of the kidneys.
Now Xarelto is the most studied drug for the prevention of DVT and PE in patients who have undergone surgery to replace the hip or knee joint. The efficacy and safety of Xarelto were studied in the framework of the international clinical study RECORD, which consisted of 4 parts, in which a total of 12.5 thousand patients participated. In this clinical trial, Xarelto (10 mg – 1 tablet 1 time per day) was compared with low-molecular-weight heparin enoxaparin administered to parenteral patients daily at a dosage of 40 mg, as well as with the US-approved dosage regimen of the drug Enoxaparin for knee joint prosthetics in dosage 30 mg 2 times a day.